Clinical management and discontinuation of treatment in patients with recent onset rheumatoid arthritis in a rheumatology consultation

Rosado, Z. Rosales; Font, J.; Rodriguez, I. Hernández; Mateos, Leticia León; Alcázar, L.; Jover, Juan A.

doi:10.1016/j.reumae.2020.08.003

Cited by 1 publication

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…csDMARDs are relatively safe and efficacious. Commonly used conventional DMARDs include methotrexate, sulfasalazine, leflunomide, and hydroxychloroquine [ 30 ]. In patients with definite RA, treatment with DMARDs is started as soon as the RA diagnosis is made.…”

Section: Current Therapy For Ramentioning

confidence: 99%

Adipose-Derived Stem Cell Exosomes as a Novel Anti-Inflammatory Agent and the Current Therapeutic Targets for Rheumatoid Arthritis

Chang

Chiou

et al. 2022

Biomedicines

View full text Add to dashboard Cite

Patients with rheumatoid arthritis (RA), a chronic inflammatory joint disorder, may not respond adequately to current RA treatments. Mesenchymal stem cells (MSCs) elicit several immunomodulatory and anti-inflammatory effects and, thus, have therapeutic potential. Specifically, adipose-derived stem cell (ADSC)-based RA therapy may have considerable potency in modulating the immune response, and human adipose tissue is abundant and easy to obtain. Paracrine factors, such as exosomes (Exos), contribute to ADSCs’ immunomodulatory function. ADSC-Exo-based treatment can reproduce ADSCs’ immunomodulatory function and overcome the limitations of traditional cell therapy. ADSC-Exos combined with current drug therapies may provide improved therapeutic effects. Using ADSC-Exos, instead of ADSCs, to treat RA may be a promising cell-free treatment strategy. This review summarizes the current knowledge of medical therapies, ADSC-based therapy, and ADSC-Exos for RA and discusses the anti-inflammatory properties of ADSCs and ADSC-Exos. Finally, this review highlights the expanding role and potential immunomodulatory activity of ADSC-Exos in patients with RA.

show abstract

Section: Current Therapy For Ramentioning

confidence: 99%